The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis

International Immunopharmacology

Volumn 42, Issue , 2017, Pages 168-175

  Han, Ying ^a   Zeng, Ajuan ^a   Liao, Huiyu ^a   Liu, Yanmin ^a   Chen, Yuhan ^a   Ding, Huiguo ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

CHB; Chronic hepatitis B; Efficacy; Entecavir; HBV; Safety; Tenofovir

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; ENTECAVIR; PHOSPHATE; PHOSPHORUS; TENOFOVIR; VIRUS DNA; GUANINE;

ARTICLE; CHRONIC HEPATITIS B; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; HUMAN; HYPOPHOSPHATEMIA; INCIDENCE; KIDNEY FUNCTION; KIDNEY INJURY; LIVER CIRRHOSIS; LIVER FUNCTION; META ANALYSIS; OSTEOPENIA; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; PHYSIOLOGY; TREATMENT OUTCOME; VIRUS LOAD;

ACUTE KIDNEY INJURY; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; HYPOPHOSPHATEMIA; LIVER CIRRHOSIS; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84998996695     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.11.022     Document Type: Article

References (39)

1. [1] Busch, K., Thimme, R., Natural history of chronic hepatitis B virus infection. Med. Microbiol. Immunol. 204 (2015), 5–10.
2. [2] Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G., Ott, J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
3. [3] Ali Riza Koksal, H.A., Boga, S., Ergun, M., Bayram, M., Ozguven, B.Y., Alkim, C., Effect of entecavir and tenofovir treatment on noninvasive fibrosis scores: which one is better?. Am. J. Ther. 23 (2016), e429–e438.
4. [4] Roche, B., Samuel, D., Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. Clin. Liver Dis. 17 (2013), 451–473.
5. [5] Yun-Fan Liaw, C.-M.C., Hepatitis B virus infection. Lancet 373 (2009), 582–592.
6. [6] Pol, S., Lampertico, P., First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J. Viral Hepat. 19 (2012), 377–386.
7. [7] Han, S.H., Tran, T.T., Management of chronic hepatitis B: an overview of practice guidelines for primary care providers. J. Am. Board Fam. Med. 28 (2015), 822–837.
8. [8] Zuo, S.R., Zuo, X.C., Wang, C.J., Ma, Y.T., Zhang, H.Y., Li, Z.J., Song, L.Y., Deng, Z.Z., Liu, S.K., A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection. J. Clin. Pharmacol. 55 (2015), 288–297.
9. [9] Wang, M.Q., He, J.J., Li, G., Widmalm, S.E., The effect of physiological nonbalanced occlusion on the thickness of the temporomandibular joint disc: a pilot autopsy study. J. Prosthet. Dent. 99 (2008), 148–152.
10. [10] Knobloch, K., Yoon, U., Vogt, P.M., Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J. Craniomaxillofac. Surg. 39 (2011), 91–92.
11. [11] Batirel, A., Guclu, E., Arslan, F., Kocak, F., Karabay, O., Ozer, S., Turanli, M., Mert, A., Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: a multicenter real-life study. Int. J. Infect. Dis. 28 (2014), 153–159.
12. [12] Shi, H., Huang, M., Lin, G., Li, X., Wu, Y., Jie, Y., Chong, Y., Efficacy comparison of tenofovir and entecavir in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Biomed. Res. Int., 2016, 2016, 6725073.
13. [13] Yu, H.M., Kwon, S.Y., Kim, J., Chung, H.A., Kwon, S.W., Jeong, T.G., An, S.H., Jeong, G.W., Yun, S.U., Min, J.K., et al. Virologic response and safety of tenofovir versus entecavir in treatment-naive chronic Hepatitis B patients. Saudi J. Gastroenterol. 21 (2015), 146–151.
14. [14] Liaw, Y.F., Sheen, I.S., Lee, C.M., Akarca, U.S., Papatheodoridis, G.V., Suet-Hing Wong, F., Chang, T.T., Horban, A., Wang, C., Kwan, P., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53 (2011), 62–72.
15. [15] Gao, L., Trinh, H.N., Li, J., Nguyen, M.H., Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment. Pharmacol. Ther. 39 (2014), 629–637.
16. [16] Nghiem, B., Ha, H.N.T., Rosenblatt, L., Nghiem, D., Nguyen, M.H., Treatment outcomes with first-line therapies with entecavir and tenofovir in treatment-naive chronic hepatitis B patients in a routine clinical practice. J. Clin. Gastroenterol. 50 (2016), 169–174.
17. [17] AOKO, F.G., Cetinkaya, Z.A., Senates, E., Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B. Hepato-Gastroenterology 59 (2012), 477–480.
18. [18] Ozaras, R., Mete, B., Ceylan, B., Ozgunes, N., Gunduz, A., Karaosmanoglu, H., Cagatay, A., Gokturk, K., Erdem, L., Kocak, F., et al. First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment. Eur. J. Gastroenterol. Hepatol. 26 (2014), 774–780.
19. [19] Kwon, Y.J., Lee, H.S., Park, M.J., Shim, S.G., Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t) ide-naive patients with chronic hepatitis B. Niger. J. Clin. Pract. 18 (2015), 796–801.
20. [20] Jayakumar, R., Joshi, Y.K., Singh, S., Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J. Lab. Physicians 4 (2012), 10–16.
21. [21] Dogan, Z., Filik, L., Ergul, B., Sarikaya, M., Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis. Saudi J. Gastroenterol., 2015.
22. [22] Sriprayoon, T., Lueangarun, S., Suwanwela, C., Pattaranutaporn, P., Tanwandee, T., Mo1833 efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial. Gastroenterology, 142, 2012, S-695.
23. [23] Miria Miquel, O.N., Trapero-Marugan, M., Diaz-Sanchez, A., Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann. Hepatol. 12 (2013), 205–212.
24. [24] Goyal, S.K., Dixit, V.K., Shukla, S.K., Ghosh, J., Behera, M., Tripathi, M., Gupta, N., Ranjan, A., Jain, A.K., Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis. Indian J. Gastroenterol. 34 (2015), 286–291.
25. [25] Koklu, S., Tuna, Y., Gulsen, M.T., Demir, M., Koksal, A.S., Kockar, M.C., Aygun, C., Coban, S., Ozdil, K., Ataseven, H., et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 11 (2013), 88–94.
26. [26] Idilman, R., Gunsar, F., Koruk, M., Keskin, O., Meral, C.E., Gulsen, M., Elhan, A.H., Akarca, U.S., Yurdaydin, C., Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting. J. Viral Hepat. 22 (2015), 504–510.
27. [27] Evangelos Cholongitas, G.V.P., Goulisa, J., Vlachogiannakos, J., Stylianos Karatapanisc, J.K., Vasiliadise, T., Kontosd, G., Anastasios Karlaftisb, E.A., The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Ann. Gastroenterol. 28 (2015), 109–117.
28. [28] Papatheodoridis, G.V., Dalekos, G.N., Yurdaydin, C., Buti, M., Goulis, J., Arends, P., Sypsa, V., Manolakopoulos, S., Mangia, G., Gatselis, N., et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J. Hepatol. 62 (2015), 363–370.
29. [29] Hung, C.H., Hu, T.H., Lu, S.N., Lee, C.M., Chen, C.H., Kee, K.M., Wang, J.H., Tsai, M.C., Kuo, Y.H., Chang, K.C., et al. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. Antimicrob. Agents Chemother. 59 (2015), 3168–3173.
30. [30] Tsai, M.C., Chen, C.H., Tseng, P.L., Hung, C.H., Chiu, K.W., Wang, J.H., Lu, S.N., Lee, C.M., Chang, K.C., Yen, Y.H., et al. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin. Microbiol. Infect. 22:95 (2016), e91–e97.
31. [31] Tien, C., Xu, J.J., Chan, L.S., Chang, M., Lim, C., Lee, S., Huh, B., Shinada, S., Bae, H.S., Fong, T.L., Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig. Dis. Sci. 60 (2015), 566–572.
32. [32] Mingxing Huang, Y.J., Shi, H., Li, X., Li, X., Wu, Y., Lin, G., Chong, Y., Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in China. Int. J. Clin. Exp. Med. 8 (2015), 666–673.
33. [33] Nghi, B., Ha, K.K., Ha, N.B., Chaung, K.T., Trinh, H.N., Nguyen, M.H., Renal function in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or entecavir monotherapy a matched case-cohort study. J. Clin. Gastroenterol. 49 (2015), 873–877.
34. [34] Mauss, S., Berger, F., Filmann, N., Hueppe, D., Henke, J., Hegener, P., Athmann, C., Schmutz, G., Herrmann, E., Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J. Hepatol. 55 (2011), 1235–1240.
35. [35] Mallet, V., Schwarzinger, M., Vallet-Pichard, A., Fontaine, H., Corouge, M., Sogni, P., Pol, S., Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. Clin. Gastroenterol. Hepatol. 13 (2015), 1181–1188, e1181.
36. [36] Gish, R.G., Clark, M.D., Kane, S.D., Shaw, R.E., Mangahas, M.F., Baqai, S., Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 10 (2012), 941–946 (quiz e968).
37. [37] Govan, L., Wu, O., Xin, Y., Hutchinson, S.J., Hawkins, N., Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis. Eur. J. Gastroenterol. Hepatol. 27 (2015), 882–894.
38. [38] Woo, G., Tomlinson, G., Nishikawa, Y., Kowgier, M., Sherman, M., Wong, D.K., Pham, B., Ungar, W.J., Einarson, T.R., Heathcote, E.J., Krahn, M., Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139 (2010), 1218–1229.
39. [39] Lok BJM, A.S.F., Brown, R.S. Jr., Wong, J.B., Ahmed, A.T., Farah, W., Almasri, J., Alahdab, F., Benkhadra, K., Mouchli, M.A., Singh, S., Mohamed, E.A., Dabrh, A.M.A., Prokop, L.J., Wang, Z., Murad, M.H., Mohammed, K., Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 63 (2016), 284–306.